Treatment with anti-PD-1 and anti-CTLA-4 as single agents resulted in T-cell infiltration into tumors; when anti-PD-1 and anti-CTLA-4 were combined, even greater numbers of CD3+ T cells and PD-L1+ cells were found within the tumor mass (Fig 2). Here, CD274 is linked to neoplasm.